|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.37 USD | -0.88% |
|
-7.13% | +31.46% |
| Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
| Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Enanta Pharmaceuticals, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported sales was USD 79.2 million compared to USD 86.16 million a year ago. Net loss was USD 133.82 million compared to USD 121.76 million a year ago.
Basic loss per share from continuing operations was USD 6.38 compared to USD 5.91 a year ago. Diluted loss per share from continuing operations was USD 6.38 compared to USD 5.91 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +31.46% | 262M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
ENANTA PHARMACEUTICALS, INC. 
